Latest Renal cell carcinoma Stories
Data Support Adoption of Stable Disease as Response Criterion, Raise Intriguing Hypotheses about Sequential Therapy and Utility of IL-2 as Salvage Option CHICAGO, May 31, 2014 /PRNewswire/
Reduced kidney function may increase the risk of developing kidney and urothelial cancers.
Retrospective Analysis Demonstrates Survival Benefits for Patients with Stable and Progressive Disease after HD IL-2 in the Modern Era Suggesting Appropriate Drug Sequencing May Improve Outcomes
LAUSANNE, Switzerland, May 28, 2014 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that
WHIPPANY, N.J., May 14, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc.
Retrospective Study of Roswell Park Patients Documents Safety and Benefit of Complex Immunotherapy Buffalo, NY (PRWEB) May 06, 2014 A retrospective study
LONDON, May 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Minimally Invasive Procedure Showcases Future Treatment Options Pleasanton, CA (PRWEB) May 02, 2014 Sanarus Technologies welcomes the release of an abstract
WHIPPANY, N.J. and THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., April 23, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc.
A new study published in The Oncologist journal shows that a subset of patients with advanced differentiated thyroid cancer (DTC) and multiple comorbidities in which full-dose sorafenib is considered
- Large; stout; burly.